09/559,881 6494.US.O2 Response to OA Page 2 of 10

REMARKS

Claims 1-2, 7-8, and 19-20, 22, and 24 are pending in the application. Claim 7 has been cancelled. Accordingly, 1-2, 8, and 19-20, 22, and 24 are under consideration. Claims 1, 2, 20, and 22 are allowed.

Claim 8 has been amended to depend from Claim 2.

Claim 19 has been amended to delete species not within the scope of Claim 1, wherein Z is other than a pyrrolidinyl moiety. Applicants respectfully reserve the right to file divisional applications on any non-pending or non-elected subject matter.

Claim 22 has been amended to recite a method of treating a disorder wherein the disorder is pain. Claim 22, as amended, provides antecedent basis for Claim 24.

As such, it is respectfully submitted that the rejections under 35 U.S.C. § 112 are overcome. It is believed that the application is in a condition for allowance and notification of the same is respectfully requested.

The Examiner is cordially invited to contact the undersigned by telephone at the phone number provided below to further facilitate the prosecution of the application, if necessary.

Respectfully submitted, Schrimpf, et al.

ABBOTT LABORATORIES

Customer No. 23492

Telephone: (847) 937-8272 Facsimile: (847) 938-2623

Portia Chen

Registration No. 44,075 Attorney for Applicants